GlassScriptPhysician profile
Padmaja Chilukoti
NPI 1053704148
$4,562.52
in general payments reported to CMS, 2019-2025
36 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.15 · 2022: $1,234 · 2023: $1,351 · 2024: $962 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $602.18 | 2022-2025 | Korlym |
| Lilly USA, LLC | $541.82 | 2022-2025 | Mounjaro, Lyumjev, Baqsimi |
| Novo Nordisk INC | $489.03 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $399.21 | 2022-2023 | Lupron Depot, Synthroid |
| Abbott Laboratories | $373.63 | 2023-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Merck Sharp & Dohme LLC | $279.19 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Amgen INC. | $248.11 | 2022-2025 | Evenity, Prolia, Prolia |
| Xeris Pharmaceuticals, INC. | $223.32 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $157.33 | 2023-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $119.26 | 2022-2023 | Unithroid |
| Neurocrine Biosciences, INC. | $110.94 | 2025 | |
| Sanofi-Aventis U.S. LLC | $110.33 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $88.46 | 2025 | Strensiq |
| Antares Pharma, INC. | $71.09 | 2022 | |
| Dexcom, INC. | $69.88 | 2022-2025 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.26 | 2022-2023 | |
| Medtronic, INC. | $65.05 | 2024-2025 | Minimed 780g |
| Azurity Pharmaceuticals, INC. | $62.35 | 2023-2024 | Triptodur, Triptodur |
| Ascendis Pharma Endocrinology INC | $49.82 | 2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $45.89 | 2022 | |
| Biomarin Pharmaceutical INC. | $43.04 | 2022-2025 | Voxzogo 1.2mg |
| Glaxosmithkline, LLC. | $40.30 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $39.03 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $38.74 | 2022-2025 | Bylvay |
| Amryt Pharma Holdings LTD | $35.89 | 2022-2023 | Mycapssa |
| Tolmar Pharmaceuticals, INC. | $31.10 | 2022 | |
| Corium, LLC | $23.25 | 2023 | Azstarys |
| Insulet Corporation | $19.32 | 2024 | Omnipod |
| Pfizer INC. | $17.67 | 2022 | |
| Rgh Enterprises LLC | $16.56 | 2023 | |
| Qiagen, LLC | $15.57 | 2023 | Quantiferon-Tb Gold Plus |
| Zealand Pharma US, INC. | $15.15 | 2021 | |
| Ascensia Diabetes Care US INC. | $14.10 | 2024 | |
| Ibsa Pharma INC. | $13.78 | 2023 | Tirosint, Licart |
| Tandem Diabetes Care, INC. | $13.37 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmaja Chilukoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.